| Issue Type | XXXX |
|---|---|
| Country | United States |
| Industry | XXXX |
| Region | XXXX |
| Maturity Date | 2039-02-01 |
| Par Value | 2000 |
| Callable | XXXX |
| Next Call Date | XXXX |
| Call Type | XXXX |
| Call Price (%) | XXXX |
| Series | XXXX |
| Class | XXXX |
| Maturity Structure | XXXX |
| Amount Outstanding (mil) | 466.32 |
| Coupon | 6.4 |
|---|---|
| Coupon Type | XXXX |
| Coupon Frequency | XXXX |
| First Coupon Date | XXXX |
| Last Coupon Date | XXXX |
| Sinking Fund | XXXX |
|---|---|
| Security | XXXX |
| Subordination | XXXX |
| Debt Type | XXXX |
| Issue Date | XXXX |
|---|---|
| Dated Date | XXXX |
| Issue Size (mil) | 1000 |
| Min. Piece | XXXX |
| Min. Increment | XXXX |
This AMGEN Inc. corporate note has a X.X % fixed rate coupon paid on a XXXX basis. It was issued on MAR 12, 2000 with an issue size of XXX million USD and matures on DEC 9, 2000 with a last coupon date of FEB 28, 2020. |
Amgen Inc., founded in 1980 and headquartered in Thousand Oaks, California, is a leading global biotechnology company focused on discovering, developing, and delivering innovative human therapeutics. Specializing in treatments for serious illnesses, Amgen's key products include biologic medicines for cancer, kidney disease, and osteoporosis, contributing significantly to the advancement of healthcare.